(Q40911610)

24 September 2017

title

Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase (English)

1 reference

24 September 2017

0 references

prostatic hypertrophy

1 reference

Polat O

1

1 reference

24 September 2017

Ozbey I

2

1 reference

24 September 2017

Gül O

3

1 reference

24 September 2017

Demirel A

4

1 reference

24 September 2017

Bayraktar Y

5

1 reference

24 September 2017

publication date

1 January 1997

1 reference

International Urology and Nephrology

24 September 2017

published in

1 reference

24 September 2017

volume

29

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

323-330

1 reference

Androgen ablation and blockade in the treatment of benign prostatic hyperplasia

24 September 2017

cites work

1 reference

12 December 2020

Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans

1 reference

12 December 2020

Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association

1 reference

12 December 2020

Nonoperative management of benign prostatic hyperplasia

1 reference

12 December 2020

Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men

1 reference

12 December 2020

Normal histology of the prostate.

1 reference

12 December 2020

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

12 December 2020

This month in investigative urology: alpha adrenergic innervation of the prostate: insights into pharmacotherapy of BPH

1 reference

12 December 2020

Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.

1 reference

12 December 2020

The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.

1 reference

12 December 2020

Urodynamics in benign prostatic hyperplasia: a survey.

1 reference

12 December 2020

Effect of finasteride on prostate-specific antigen density

1 reference

12 December 2020

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Pathology of benign prostatic hyperplasia. Insight into etiology

1 reference

12 December 2020

The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02550930

1 reference

24 September 2017

1 reference